ArticleParasites & vectors2020
Bioassay and molecular monitoring of insecticide resistance status in Aedes albopictus populations from Greece, to support evidence-based vector control.
Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Present and Future of Mosquito-Borne Disease Control in Europe with a Specific Focus on the Mediterranean.Insects · 2026Review
- Metabolic resistance drives cross-resistance in Aedes albopictus to pyriproxyfen and pyrethroid insecticides.PloS one · 2026Article
- Tracking pyrethroid resistance in arbovirus mosquito vectors: mutations I1532T and F1534C in Aedes albopictus across Europe.Parasites & vectors · 2025Article
- Development and application of a PCR-RFLP assay revealing widespread distribution of the pyrethroid resistance-associated VGSC V1016G mutation in Aedes albopictus from Guangyuan City, Sichuan Province of China.Parasites & vectors · 2025Article
- Aedes aegypti strain selected with Bacillus thuringiensis svar. israelensis larvicide for 50 generations remains susceptible and exhibited increased fitness.Parasites & vectors · 2025Article
- The origin and insecticide resistance of Aedes albopictus mosquitoes established in southern Mozambique.Parasites & vectors · 2024Article
- Diversity and distribution of sodium channel mutations in Aedes albopictus (Diptera: Culicidae).Journal of medical entomology · 2024Article
- Molecular monitoring of insecticide resistance in major disease vectors in Armenia.Parasites & vectors · 2024Article
- Aedes aegypti CCEae3A carboxylase expression confers carbamate, organophosphate and limited pyrethroid resistance in a model transgenic mosquito.PLoS neglected tropical diseases · 2024Article
- First comprehensive report of the resistance ofHeliyon · 2023Article
- Geographic distribution of the V1016G knockdown resistance mutation in Aedes albopictus: a warning bell for Europe.Parasites & vectors · 2022Article
- Mosquito population structure, pathogen surveillance and insecticide resistance monitoring in urban regions of Crete, Greece.PLoS neglected tropical diseases · 2022Article
- The tiger mosquito in Lebanon two decades after its introduction: A growing health concern.PLoS neglected tropical diseases · 2022Article
- Effects of Selection to Diflubenzuron andInsects · 2021Article
- Review
- Article
- VectorMap-GR: A local scale operational management tool for entomological monitoring, to support vector control activities in Greece and the Mediterranean Basin.Current research in parasitology & vector-borne diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAedes albopictus has a well-established presence in southern European countries, associated with recent disease outbreaks (e.g. chikungunya). Development of insecticide resistance in the vector is a major concern as its control mainly relies on the use of biocides. Data on the species' resistance status are essential for efficient and sustainable control. To date the insecticide resistance status of Ae. albopictus populations from Greece against major insecticides used in vector control remains largely unknown.
methodsWe investigated the insecticide resistance status of 19 Ae. albopictus populations from 11 regions of Greece. Bioassays were performed against diflubenzuron (DFB), Bacillus thuringiensis var. israelensis (Bti), deltamethrin and malathion. Known insecticide resistance loci were molecularly analysed, i.e. voltage-gated sodium channel (VGSC) mutations associated with pyrethroid resistance; presence and frequency of carboxylesterases 3 (CCEae3a) and 6 (CCEae6a) gene amplification associated with organophosphate (OP) resistance and; chitin synthase-1 (CHS-1) for the possible presence of DFB resistance mutations.
resultsBioassays showed full susceptibility to DFB, Bti and deltamethrin, but resistance against the OP malathion (range of mortality: 55.30-91.40%). VGSC analysis revealed a widespread distribution of the mutations F1534C (in all populations, with allelic frequencies between 6.6-68.3%), and I1532T (in 6 populations; allelic frequencies below 22.70%), but absence of V1016G. CCE gene amplifications were recorded in 8 out of 11 populations (overall frequency: 33%). Co-presence of the F1534C mutation and CCEae3a amplification was reported in 39 of the 156 samples analysed by both assays. No mutations at the CHS-1 I1043 locus were detected.
conclusionsThe results indicate: (i) the suitability of larvicides DFB and Bti for Ae. albopictus control in Greece; (ii) possible incipient pyrethroid resistance due to the presence of kdr mutations; and (iii) possible reduced efficacy of OPs, in a scenario of re-introducing them for vector control. The study highlights the need for systematic resistance monitoring for developing and implementing appropriate evidence-based control programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.